Alan D. Snow, Ph.D., a former Research Associate Professor of Pathology at the University of Washington founded the Company in 1996 to accelerate new discoveries pertaining to proteoglycan technologies and their relationship to amyloid related diseases. Dr. Snow was one of the first researchers who identified that beta-amyloid protein should be a target for Alzheimer's disease therapeutics. His early research involved working with the Nobel Prize winner Dr. Stanley Prusiner on identifying the role of proteoglycans in prion diseases. Dr. Snow was the first researcher who identified the existence of specific proteoglycans in beta-amyloid protein deposits in Alzheimer's disease and Downs' Syndrome.

The Company has since been successful in independently discovering three proprietary classes of compounds that inhibit and disrupt the amyloid fibril process, which include: (1) unique small molecule compounds and analogs (representing new chemical entities), (2) unique small peptides (representing new chemical entities), and (3) small carbohydrates.

The Company believes that specific and newly identified compounds within these classes will lead to exciting new therapies for the treatment of amyloid diseases. ProteoTech's team of scientists is dedicated to improving the health of individuals targeted with these dreaded diseases.